


CLAIMS:

1. A compound of Formula (I):



or pharmaceutically acceptable salts thereof, wherein:

X is N and **Y** is CH; or

X is CH and **Y** is N;

HET is a 5-membered heteroaryl ring containing one to three heteroatoms selected from nitrogen and sulfur, wherein each heteroaryl ring is optionally substituted with one to two substituents groups independently selected from **R³** and **R⁴**; or

HET is a 5-membered heteroaryl ring containing one to three heteroatoms selected from nitrogen and sulfur, wherein each heteroaryl ring is substituted with two substituents groups selected from **R^a** and **R^b**, wherein **R^a** and **R^b** together with the atoms to which they are attached form a 5-6 membered heterocyclic or heteroaryl ring which may be optionally substituted with one to two substituents selected from **R³** and **R⁴**;

R¹ is hydrogen or F;

R² is C₁₋₃ alkyl or Cl;

R³ and **R⁴** are each independently selected from:

- (a) -H,
- (b) -O R⁵,
- (c) -O- C₁₋₆alkyl-O- C₁₋₃ alkyl,
- (d) -O-C₃₋₆ cycloalkyl,
- (e) -C(O)R⁵,
- (f) C₁₋₆alkyl optionally substituted with one to three -OH, fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl, -CO₂R⁵, -O- C₁₋₆alkyl, aryl, -N(R⁵)(R⁶), or -C(O)N(R⁵)(R⁶),
- (g) C₃₋₆ cycloalkyl optionally substituted with one to three -OH, one to three fluorine, C₁₋₆alkyl, -OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, -OC₃₋₆cycloalkyl, -CO₂H, -CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆ heterocyclyl, N(R⁵)(R⁶), or -C(O)N(R⁵)(R⁶),
- (h) -CO₂R⁵,
- (i) -C(O)N(R⁵)(R⁶),
- (j) -S(O)₂N(R⁵)(R⁶),
- (k) -S(O)_n-R⁵,
- (l) a 5-6 membered heteroaryl group optionally substituted with one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, -CF₃, -OH, -(CH₂)_nCO₂R⁵, -C(O)N(R⁵)(R⁶), -N(R⁵)(R⁶), -NH-SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O- C₁₋₃ alkyl, C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally substituted with halogen and -S(O)_nC₁₋₆alkyl,
- (m) 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl group containing N, S or O, wherein each heterocycle is optionally substituted with with 1-3 substituents selected from 3-6 membered heterocyclic ring, halogen, -C₁₋₃alkyl, -C₁₋₃alkyl -O- C₁₋₃alkyl and -C₁₋₃alkyl- C(O)N(R⁵)(R⁶),
- (n) aryl,
- (o) - N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from -H, 4-6 membered heterocyclyl, -C(O)-C₁₋₃ alkyl -C(O)-C₁₋₃ cycloalkyl and -(C₁-C₆)alkyl, wherein each R⁵ and R⁶ is independently optionally

substituted with –OH, C₃₋₆ cycloalkyl, –C₁₋₃alkyl, –O– C₁₋₃alkyl, –NH–C₁₋₃ alkyl or –N–(C₁₋₃–alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclic ring optionally substituted with methyl; and

n is 0, 1, or 2.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:

X is N and **Y** is CH; or

X is CH and **Y** is N;

Het is a 5-membered heteroaryl ring selected from pyrazolyl, imidazolyl, thiazolyl and thiadiazolyl, wherein each heteroaryl ring is optionally substituted with one to two substituents groups independently selected from **R**³ and **R**⁴; or

Het is a 5-membered heteroaryl ring selected from pyrazolyl and imidazolyl, wherein each heteroaryl ring is substituted with two substituents groups selected from **R**^a and **R**^b, wherein **R**^a and **R**^b together with the atoms to which they are attached form a 5-6 membered heterocyclic or heteroaryl ring which may be optionally substituted with one to two substituents selected from **R**³ and **R**⁴;

R¹ is hydrogen or F;

R² is C₁₋₃ alkyl or Cl;

R³ and **R**⁴ are each independently selected from:

- (a) –H,
- (b) –O R⁵,
- (c) –O– C₁₋₆alkyl–O– C₁₋₃ alkyl,
- (d) –O–C₃₋₆ cycloalkyl,
- (e) –C(O)R⁵,

(f) C₁₋₆alkyl optionally substituted with one to three –OH, fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl, –CO₂R⁵, –O- C₁₋₆alkyl, aryl, –N(R⁵)(R⁶), or –C(O)N(R⁵)(R⁶),

(g) C₃₋₆ cycloalkyl optionally substituted with one to three –OH, one to three fluorine, C₁₋₆alkyl, –OC₁₋₆alkyl, C₁₋₆alkyl–OC₁₋₆alkyl, C₁₋₆alkyl–OH, CF₃, –OC₃₋₆cycloalkyl, –CO₂H, –CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆ heterocyclyl, N(R⁵)(R⁶), or –C(O)N(R⁵)(R⁶),

(h) –CO₂R⁵,

(i) –C(O)N(R⁵)(R⁶),

(j) –S(O)₂N(R⁵)(R⁶),

(k) –S(O)_n–R⁵

(l) a 5-6 membered heteroaryl group optionally substituted with one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, –CF₃, –OH, –(CH₂)_nCO₂R⁵, –C(O)N(R⁵)(R⁶), –N(R⁵)(R⁶), –NH–SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl–O– C₁₋₃ alkyl, C₁₋₆alkylhydroxyl, C₁₋₃alkyl–CN, oxo, phenyl optionally substituted with halogen and –S(O)_nC₁₋₆alkyl,

(m) 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl group containing N, S or O, wherein each heterocycle is optionally substituted with 1-3 substituents selected from 3-6 membered heterocyclic ring, halogen, C₁₋₃alkyl, and C₁₋₃alkyl–C(O)N(R⁵)(R⁶),

(n) aryl,

(o)– N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from –H, 4-6 membered heterocyclyl, –C(O)–C₁₋₃ alkyl –C(O)–C₁₋₃ cycloalkyl and –(C₁₋₆)alkyl optionally substituted with –OH, C₃₋₆ cycloalkyl, –NH–C₁₋₃ alkyl or –N–(C₁₋₃–alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 5-6 membered heterocyclic ring optionally substituted with methyl; and

n is 0 or 2 .

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:

HET is a 5-membered heteroaryl ring selected from pyrazolyl, imidazolyl, thiazolyl and thiadiazolyl, wherein each heteroaryl ring is optionally substituted with one to two substituents groups independently selected from **R³** and **R⁴**;

R³ and **R⁴** are each independently selected from:

- (a) -H,
- (b) -O R⁵,
- (c) -O- C₁₋₆alkyl-O- C₁₋₃ alkyl
- (d) -O-C₃₋₆ cycloalkyl,
- (e) -C(O)R⁵,
- (f) C₁₋₆alkyl optionally substituted with one to three -OH, fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl, -CO₂R⁵, -O- C₁₋₆alkyl, aryl, -N(R⁵)(R⁶), or -C(O)N(R⁵)(R⁶),
- (g) C₃₋₆ cycloalkyl optionally substituted with one to three -OH, one to three fluorine, C₁₋₆alkyl, -OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, -OC₃₋₆cycloalkyl, -CO₂H, -CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆ heterocyclyl, N(R⁵)(R⁶), or -C(O)N(R⁵)(R⁶),
- (h) -CO₂R⁵,
- (i) -C(O)N(R⁵)(R⁶),
- (j) -S(O)₂N(R⁵)(R⁶),
- (k) -S(O)_n-R⁵
- (l) a 5-6 membered heteroaryl group optionally substituted with one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, -CF₃, -OH, -(CH₂)_nCO₂R⁵, -C(O)N(R⁵)(R⁶), -N(R⁵)(R⁶), -NH-SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O- C₁₋₃ alkyl, C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally substituted with halogen and -S(O)_nC₁₋₆alkyl,

(m) 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl group containing N, S or O, wherein each heterocycle is optionally substituted with 1-3 substituents selected from 3-6 membered heterocyclic ring, halogen, C₁₋₃alkyl, and C₁₋₃alkyl- C(O)N(R⁵)(R⁶),

(n) aryl,

(o)- N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from -H, 4-6 membered heterocyclyl, -C(O)-C₁₋₃ alkyl -C(O)-C₁₋₃ cycloalkyl and -(C₁-C₆)alkyl optionally substituted with -OH, C₃₋₆ cycloalkyl, -NH-C₁₋₃ alkyl or -N-(C₁₋₃-alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 5-6 membered heterocyclic ring optionally substituted with methyl; and

n is 0 or 2 .

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:

HET is a 5-membered heteroaryl ring selected from pyrazolyl and imidazolyl, wherein each heteroaryl ring is substituted with two substituents groups selected from **R^a** and **R^b**; wherein **R^a** and **R^b** together with the atoms to which they are attached form a 5-6 membered heterocyclic or heteroaryl ring which may be optionally substituted with one to two substituents selected from **R³** and **R⁴**;

R³ and **R⁴** are each independently selected from:

(a) -H,

(b) -O R⁵,

(c) -O- C₁₋₆alkyl-O- C₁₋₃ alkyl

(d) -O-C₃₋₆ cycloalkyl,

(e) -C(O)R⁵,

(f) C₁₋₆alkyl optionally substituted with one to three -OH, fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl, -CO₂R⁵, -O- C₁₋₆alkyl, aryl, -N(R⁵)(R⁶), or -C(O)N(R⁵)(R⁶),

- (g) C₃₋₆ cycloalkyl optionally substituted with one to three –OH, one to three fluorine, C₁₋₆alkyl, –OC₁₋₆alkyl, C₁₋₆alkyl–OC₁₋₆alkyl, C₁₋₆alkyl–OH, CF₃, –OC₃₋₆cycloalkyl, –CO₂H, –CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆ heterocyclyl, N(R⁵)(R⁶), or –C(O)N(R⁵)(R⁶),
- (h) –CO₂R⁵,
- (i) –C(O)N(R⁵)(R⁶),
- (j) –S(O)₂N(R⁵)(R⁶),
- (k) –S(O)_n–R⁵
- (l) a 5-6 membered heteroaryl group optionally substituted with one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, –CF₃, –OH, –(CH₂)_nCO₂R⁵, –C(O)N(R⁵)(R⁶), –N(R⁵)(R⁶), –NH–SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl–O–C₁₋₃alkyl, C₁₋₆alkylhydroxyl, C₁₋₃alkyl–CN, oxo, phenyl optionally substituted with halogen and –S(O)_nC₁₋₆alkyl,
- (m) 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl group containing N, S or O, wherein each heterocycle is optionally substituted with 1-3 substituents selected from 3-6 membered heterocyclic ring, halogen, C₁₋₃alkyl, and C₁₋₃alkyl–C(O)N(R⁵)(R⁶),
- (n) aryl,
- (o)– N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from –H, 4-6 membered heterocyclyl, –C(O)–C₁₋₃alkyl –C(O)–C₁₋₃cycloalkyl and –(C₁₋₆)alkyl optionally substituted with –OH, C₃₋₆cycloalkyl, –NH–C₁₋₃alkyl or –N–(C₁₋₃alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 6 membered heterocyclic ring optionally substituted with methyl; and

n is 0 or 2 .

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: **HET** is pyrazolyl optionally substituted with one to two substituents groups selected from **R³** and **R⁴**.

6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:

HET is a 5-membered heteroaryl ring selected from pyrazolyl and imidazolyl, wherein each heteroaryl ring is substituted with two substituents groups selected from **R^a** and **R^b**; wherein **R^a** and **R^b** together with the atoms to which they are attached form a 5-6 membered heteroaryl ring such that **HET** is a bicyclic heteroaryl ring selected from imidazopyridine and pyrazolopyridine which may be optionally substituted one to two substituents selected from **R³** and **R⁴**.

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Y is CH;

R¹ is F;

R² is selected from methyl and Cl;

HET is selected from imidazopyridine and pyrazolopyridine which may be optionally substituted one to two substituents selected from **R³** and **R⁴**;

R³ and **R⁴** are each independently selected from:

- (a) -H,
- (b) -O R⁵,
- (c) -O- C₁₋₆alkyl-O- C₁₋₃ alkyl
- (d) -O-C₃₋₆ cycloalkyl,
- (e) -C(O)R⁵,
- (f) C₁₋₆alkyl optionally substituted with one to three -OH, fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl, -CO₂R⁵, -O- C₁₋₆alkyl, aryl, -N(R⁵)(R⁶),
or -C(O)N(R⁵)(R⁶),
- (g) C₃₋₆ cycloalkyl optionally substituted with one to three -OH, one to three fluorine, C₁₋₆alkyl, -OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, -OC₃₋₆cycloalkyl, -CO₂H, -CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆ heterocyclyl, N(R⁵)(R⁶),
or -C(O)N(R⁵)(R⁶),

- (h) $-\text{CO}_2\text{R}^5$,
- (i) $-\text{C}(\text{O})\text{N}(\text{R}^5)(\text{R}^6)$,
- (j) $-\text{S}(\text{O})_2\text{N}(\text{R}^5)(\text{R}^6)$,
- (k) $-\text{S}(\text{O})_2-\text{R}^5$
- (l) a 5-6 membered heteroaryl group optionally substituted with one to three groups selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, halogen, $-\text{CF}_3$, $-\text{OH}$, $-(\text{CH}_2)\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{N}(\text{R}^5)(\text{R}^6)$, $-\text{N}(\text{R}^5)(\text{R}^6)$, $-\text{NH}-\text{SO}_2\text{C}_{1-6}$ alkyl, C_{1-6} alkoxyl, C_{1-6} alkyl-O- C_{1-3} alkyl, C_{1-6} alkylhydroxyl, C_{1-3} alkyl-CN, oxo, phenyl optionally substituted with halogen and $-\text{S}(\text{O})_2\text{C}_{1-6}$ alkyl,
- (m) 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl group containing N, S or O, wherein each heterocycle is optionally substituted with 1-3 substituents selected from 3-6 membered heterocyclic ring, halogen, C_{1-3} alkyl, or C_{1-3} alkyl- $\text{C}(\text{O})\text{N}(\text{R}^5)(\text{R}^6)$,
- (n) aryl,
- (o) $-\text{N}(\text{R}^5)(\text{R}^6)$;

R^5 and R^6 are each independently selected from $-\text{H}$, 4-6 membered heterocyclyl, $-\text{C}(\text{O})-\text{C}_{1-3}$ alkyl $-\text{C}(\text{O})-\text{C}_{1-3}$ cycloalkyl and $-(\text{C}_{1-6})$ alkyl optionally substituted with $-\text{OH}$, C_{3-6} cycloalkyl, $-\text{NH}-\text{C}_{1-3}$ alkyl or $-\text{N}-(\text{C}_{1-3}\text{-alkyl})_2$; or

R^5 and R^6 together with the nitrogen atom to which they are attached form a 6 membered heterocyclic ring optionally substituted with methyl.

8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Y is CH;

R¹ is F;

R² is selected from methyl and Cl;

HET is imidazopyridine which may be optionally substituted with one to two substituents selected from **R**³ and **R**⁴;

R³ and **R⁴** are each independently selected from:


- (a) -H,
- (b) -O R⁵,
- (c) -O- C₁₋₆alkyl-O- C₁₋₃ alkyl
- (d) -O-C₃₋₆ cycloalkyl,
- (e) -C(O)R⁵,
- (f) C₁₋₆alkyl optionally substituted with one to three -OH, fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl, -CO₂R⁵, -O- C₁₋₆alkyl, aryl, -N(R⁵)(R⁶), or -C(O)N(R⁵)(R⁶),
- (g) C₃₋₆ cycloalkyl optionally substituted with one to three -OH, one to three fluorine, C₁₋₆alkyl, -OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, -OC₃₋₆cycloalkyl, -CO₂H, -CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆ heterocyclyl, N(R⁵)(R⁶), or -C(O)N(R⁵)(R⁶),
- (h) -CO₂R⁵,
- (i) -C(O)N(R⁵)(R⁶),
- (j) -S(O)₂N(R⁵)(R⁶),
- (k) -S(O)₂-R⁵
- (l) a 5-6 membered heteroaryl group optionally substituted with one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, -CF₃, -OH, -(CH₂) CO₂R⁵, -C(O)N(R⁵)(R⁶), -N(R⁵)(R⁶), -NH-SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O- C₁₋₃ alkyl, C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally substituted with halogen and -S(O)₂C₁₋₆alkyl,
- (m) 6 membered monocyclic heterocyclyl group containing N wherein the heterocycle is optionally substituted with 1-3 substituents selected from 3-6 membered heterocyclic ring, halogen, C₁₋₃alkyl, and C₁₋₃alkyl- C(O)N(R⁵)(R⁶),
- (n) aryl,
- (o) - N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from -H, 4-6 membered heterocyclyl, -C(O)-C₁₋₃ alkyl -C(O)-C₁₋₃ cycloalkyl and -(C₁₋₆)alkyl optionally substituted with -OH, C₃₋₆ cycloalkyl, -NH-C₁₋₃ alkyl or -N-(C₁₋₃-alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 6 membered heterocyclic ring optionally substituted with methyl.

9. The compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein:

HET is :



optionally substituted one to two substituents selected from **R³** and **R⁴**;

R³ and **R⁴** are each independently selected from:

- (a) -H,
- (b) -O R⁵,
- (c) -O- C₁₋₆alkyl-O- C₁₋₃ alkyl
- (d) -O-C₃₋₆ cycloalkyl,
- (e) -C(O)R⁵,
- (f) C₁₋₆alkyl optionally substituted with one to three -OH, fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl, -CO₂R⁵, -O- C₁₋₆alkyl, aryl, -N(R⁵)(R⁶),
or -C(O)N(R⁵)(R⁶),
- (g) C₃₋₆ cycloalkyl optionally substituted with one to three -OH, one to three fluorine, C₁₋₆alkyl, -OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, -OC₃₋₆cycloalkyl, -CO₂H, -CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆ heterocyclyl, N(R⁵)(R⁶),
or -C(O)N(R⁵)(R⁶),
- (h) -CO₂R⁵,
- (i) -C(O)N(R⁵)(R⁶),
- (j) -S(O)₂N(R⁵)(R⁶),
- (k) -S(O)₂-R⁵
- (l) a 5-6 membered heteroaryl group optionally substituted with one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, -CF₃, -OH, -(CH₂) CO₂R⁵, -C(O)N(R⁵)(R⁶), -


$N(R^5)(R^6)$, $-NH-SO_2C_{1-6}alkyl$, $C_{1-6}alkoxyl$, $C_{1-6}alkyl-O-C_{1-3}alkyl$, $C_{1-6}alkylhydroxyl$, $C_{1-3}alkyl-CN$, oxo, phenyl optionally substituted with halogen and $-S(O)_2C_{1-6}alkyl$,
 (m) 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl group containing N, S or O, wherein each heterocycle is optionally substituted with 1-3 substituents selected from 3-6 membered heterocyclic ring, halogen, $C_{1-3}alkyl$, and $C_{1-3}alkyl-C(O)N(R^5)(R^6)$,
 (n) aryl,
 (o) $-N(R^5)(R^6)$;

R^5 and R^6 are each independently selected from $-H$, 4-6 membered heterocyclyl, $-C(O)-C_{1-3}alkyl$, $-C(O)-C_{1-3}cycloalkyl$ and $-(C_{1-6}alkyl)$ optionally substituted with $-OH$, $C_{3-6}cycloalkyl$, $-NH-C_{1-3}alkyl$ or $-N-(C_{1-3}alkyl)_2$; or

R^5 and R^6 together with the nitrogen atom to which they are attached form a 6 membered heterocyclic ring optionally substituted with methyl.

10. The compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein:


HET is :



optionally substituted one to two substituents selected from **R^3 and R^4** .

11. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:


HET is :



optionally substituted with **R^3** ,


or

HET is :



or

HET is selected from:



12. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:


X is N;

Y is CH;


R¹ is F;

R² is methyl;

HET is :















R³ is methoxy; and















13. The compound according to claim 1, namely a compound selected from the group consisting of:







Example	Structure	Example	Structure
1		54	







Example	Structure	Example	Structure
2		55	
3		56	
5		57	

Example	Structure	Example	Structure
6		58	
7		59	
8		60	







Example	Structure	Example	Structure
9		61	
10		62	
11		63	







Example	Structure	Example	Structure
12		64	
13		65	
14		66	

Example	Structure	Example	Structure
15		67	
16		68	
17		69	





Example	Structure	Example	Structure
19		70	
20		71	
21		72	

Example	Structure	Example	Structure
22		73	
23		74	
25		75	

Example	Structure	Example	Structure
26		76	
27		77	
28		78	







Example	Structure	Example	Structure
29		79	
30		80	
31		81-1	







Example	Structure	Example	Structure
32		81-2	
33		82-1	
34		82-2	

Example	Structure	Example	Structure
35		84	
36		85	


Example	Structure	Example	Structure
37		86	
38		87	
39		88	

Example	Structure	Example	Structure
40		89	
41		90	
42		91	


Example	Structure	Example	Structure
43		92	
44		93	
45		94	

Example	Structure	Example	Structure
46		95	
47		96	
48		97	


Example	Structure	Example	Structure
49		98	
50		99	
53		100	

Example	Structure	Example	Structure
		101	


14. The compound according to any one of claims 1 and 13 having the structure:




15. The compound according to any one of claims 1 and 13 having the structure:




16. The compound according to any one of claims 1 and 13 having the structure:




17. The compound according to any one of claims 1 and 13 having the structure:




18. The compound according to any one of claims 1 and 13 having the structure:



19. The compound according to any one of claims 1 and 13 having the structure:




20. The compound according to any one of claims 1 and 13 having the structure:



21. The compound according to any one of claims 1 and 13 having the structure:





24. A pharmaceutically acceptable salt of a compound according to any one of claims 13 to 23.
25. A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
26. Use of a compound according to any one of claims 1 to 24 for the manufacture of a medicament for the treatment of an autoimmune disease or allergic disorder.
27. Use of the compound according to claim 26 for the manufacture of a medicament for the treatment of an autoimmune disease or allergic disorder selected from rheumatoid arthritis, psoriasis, systemic lupus erythromatosis, lupus nephritis, scleroderma, asthma, Chronic Obstructive Pulmonary Disease (COPD), allergic rhinitis, allergic eczema, multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, type I diabetes, inflammatory bowel disease, graft versus host disease, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, uveitis and non-radiographic spondyloarthropathy.